This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT00117676
First received: June 30, 2005
Last updated: January 16, 2017
Last verified: January 2017
Results First Received: February 11, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Chronic Hepatitis B
Interventions: Drug: TDF
Drug: ADV
Drug: TDF placebo
Drug: ADV placebo
Drug: FTC/TDF

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled at study sites in North America, Europe, and Australia/New Zealand. The first participant was screened on 07 June 2005. The last study visit occurred on 19 January 2016.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
846 participants were screened.

Reporting Groups
  Description
TDF-TDF Tenofovir disoproxil fumarate (TDF) 300 mg plus placebo to match adefovir dipivoxil (ADV) (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added emtricitabine (FTC; as part of FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet) to their treatment regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their treatment regimen in the open-label period.

Participant Flow for 10 periods

Period 1:   Double-blind Period Through Week 48
    TDF-TDF   ADV-TDF
STARTED   254   128 
COMPLETED   244   121 
NOT COMPLETED   10   7 
Randomized but Not Treated                4                3 
Lost to Follow-up                1                0 
Protocol Violation                0                1 
Safety, Tolerability, or Efficacy Reason                5                2 
Withdrew Consent                0                1 

Period 2:   Open-label Period: Weeks 49 - 96
    TDF-TDF   ADV-TDF
STARTED   235 [1]   112 [1] 
COMPLETED   225   110 
NOT COMPLETED   10   2 
Lost to Follow-up                2                0 
Safety, Tolerability, or Efficacy Reason                3                1 
Withdrew Consent                5                1 
[1] 9 participants completed 48 weeks but did not continue on study.

Period 3:   Open-label Period: Weeks 97 - 144
    TDF-TDF   ADV-TDF
STARTED   225   110 
COMPLETED   219   109 
NOT COMPLETED   6   1 
Lost to Follow-up                4                1 
Safety, Tolerability, or Efficacy Reason                1                0 
Withdrew Consent                1                0 

Period 4:   Open-label Period: Weeks 145 - 192
    TDF-TDF   ADV-TDF
STARTED   219   109 
COMPLETED   209   106 
NOT COMPLETED   10   3 
Investigator's Discretion                2                0 
Lost to Follow-up                3                1 
Withdrew Consent                5                2 

Period 5:   Open-label Period: Weeks 193 - 240
    TDF-TDF   ADV-TDF
STARTED   209   106 
COMPLETED   202   103 
NOT COMPLETED   7   3 
Investigator's Discretion                1                1 
Lost to Follow-up                0                1 
Safety, Tolerability, or Efficacy Reason                2                0 
Withdrew Consent                4                1 

Period 6:   Open-label Period: Weeks 241 - 288
    TDF-TDF   ADV-TDF
STARTED   202   103 
COMPLETED   192   100 
NOT COMPLETED   10   3 
Investigator's Discretion                0                1 
Lost to Follow-up                2                1 
Protocol Violation                2                0 
Safety, Tolerability, or Efficacy Reason                1                0 
Withdrew Consent                5                1 

Period 7:   Open-label Period: Weeks 289 - 336
    TDF-TDF   ADV-TDF
STARTED   192   100 
COMPLETED   183   93 
NOT COMPLETED   9   7 
Investigator's Discretion                7                4 
Lost to Follow-up                2                2 
Withdrew Consent                0                1 

Period 8:   Open-label Period: Weeks 337 - 384
    TDF-TDF   ADV-TDF
STARTED   183   93 
COMPLETED   176   90 
NOT COMPLETED   7   3 
Investigator's Discretion                1                1 
Lost to Follow-up                3                1 
Study Site Discontinued                1                0 
Withdrew Consent                2                1 

Period 9:   Open-label Period: Weeks 385 - 432
    TDF-TDF   ADV-TDF
STARTED   82 [1]   46 [2] 
COMPLETED   82   44 
NOT COMPLETED   0   2 
Investigator’s Discretion                0                1 
Safety, Tolerability, or Efficacy Reason                0                1 
[1] 94 participants completed 384 weeks but did not continue on study.
[2] 44 participants completed 384 weeks but did not continue on study.

Period 10:   Open-label Period: Weeks 433 - 480
    TDF-TDF   ADV-TDF
STARTED   82   43 [1] 
COMPLETED   80   41 
NOT COMPLETED   2   2 
Lost to Follow-up                1                0 
Safety, Tolerability, or Efficacy Reason                1                1 
Withdrew Consent                0                1 
[1] 1 participant completed 432 weeks but did not continue on study.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Randomized and Treated Analysis Set: all participants who were randomized and received at least one dose of study medication

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added emtricitabine (FTC) to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
Total Total of all reporting groups

Baseline Measures
   TDF-TDF   ADV-TDF   Total 
Overall Participants Analyzed 
[Units: Participants]
 250   125   375 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%      1   0.8%      1   0.3% 
Between 18 and 65 years      247  98.8%      123  98.4%      370  98.7% 
>=65 years      3   1.2%      1   0.8%      4   1.1% 
Age 
[Units: Years]
Mean (Standard Deviation)
 44  (10.6)   43  (10.0)   44  (10.4) 
Gender 
[Units: Participants]
Count of Participants
     
Female      57  22.8%      28  22.4%      85  22.7% 
Male      193  77.2%      97  77.6%      290  77.3% 
Race/Ethnicity, Customized 
[Units: Participants]
     
American Indian or Alaska Native   0   0   0 
Asian   63   30   93 
Native Hawaiian or Other Pacific Islander   7   2   9 
Black or African American   8   4   12 
White   161   81   242 
More than one race   0   0   0 
Unknown or Not Reported   11   8   19 
Region of Enrollment 
[Units: Participants]
     
United States   25   11   36 
Greece   19   9   28 
Spain   15   6   21 
Turkey   11   3   14 
Italy   6   0   6 
United Kingdom   5   2   7 
France   13   5   18 
Czech Republic   7   5   12 
Canada   29   18   47 
Poland   13   11   24 
Australia   14   8   22 
Bulgaria   49   23   72 
Germany   19   11   30 
Netherlands   1   1   2 
New Zealand   24   12   36 
Baseline Alanine Aminotransferase (ALT) Above the Upper Limit of the Normal (ULN) Range [1] 
[Units: Participants]
     
Yes   236   118   354 
No   14   7   21 
[1] The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.
Prior Lamivudine or FTC Treatment 
[Units: Participants]
     
Yes   43   23   66 
No   207   102   309 
Baseline Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) 
[Units: Log10 copies/mL]
Mean (Standard Deviation)
 6.86  (1.308)   6.98  (1.266)   6.90  (1.294) 
Baseline Knodell Necroinflammatory Score [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
 7.8  (2.45)   7.8  (2.20)   7.8  (2.37) 
[1] Based on Knodell numerical scoring of liver biopsy specimens. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges 0 (best) to 14 (worst).


  Outcome Measures
  Hide All Outcome Measures

1.  Primary:   Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48   [ Time Frame: Baseline; Week 48 ]

Measure Type Primary
Measure Title Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48
Measure Description

Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.

A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40.

Time Frame Baseline; Week 48  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Randomized and Treated Analysis Set: all participants who were randomized and received at least one dose of study medication; the missing-equals-failure approach was used where participants with missing data were considered to have failed to reach the endpoint.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 250   125 
Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 
[Units: Percentage of participants]
   
Yes   70.8   48.8 
No   29.2   51.2 


Statistical Analysis 1 for Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48
Groups [1] All groups
Statistical Test Type [2] Non-Inferiority or Equivalence
Statistical Method [3] Z-test
P Value [4] <0.001
Difference in proportions [5] 23.5
95% Confidence Interval 13.2 to 33.8
Standard Error of the mean (5.2)
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  A two-sided 95% confidence interval (CI), stratified by baseline ALT (≤ 2 x ULN or > 2 x ULN) was used to evaluate the difference (tenofovir DF – adefovir dipivoxil) in the proportion of complete responders between treatment groups.
[2] Details of power calculation, definition of non-inferiority margin, and other key parameters:
  With a sample size of 200 subjects in the tenofovir DF group and 100 subjects in the adefovir dipivoxil group, a two group large-sample normal approximation test of proportions with a one-sided 0.025 significance level would have 95% power to reject the null hypothesis that the tenofovir DF treatment was inferior to the adefovir dipivoxil treatment (difference in proportions was less than -0.100) in favor of the alternative hypothesis that the tenofovir DF treatment was not inferior.
[3] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[4] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  P-value corresponds to a Z-test of the null hypothesis that the stratum-adjusted (baseline ALT ≥ 2 x ULN or > 2 x ULN) difference is 0.
[5] Other relevant estimation information:
  No text entered.



2.  Secondary:   Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48   [ Time Frame: Week 48 ]

Measure Type Secondary
Measure Title Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48
Measure Description No text entered.
Time Frame Week 48  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Randomized and Treated Analysis Set; the missing-equals-failure approach was used where participants with missing data were considered to have failed to reach the endpoint.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 250   125 
Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48 
[Units: Percentage of participants]
 93.2   63.2 


Statistical Analysis 1 for Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48
Groups [1] All groups
Statistical Test Type [2] Superiority or Other
Statistical Method [3] Z-test
P Value [4] <0.001
Difference in proportions [5] 30.3
95% Confidence Interval 21.3 to 39.2
Standard Error of the mean (4.6)
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Details of power calculation, definition of non-inferiority margin, and other key parameters:
  No text entered.
[3] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[4] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  P-value corresponds to a Z-test of the null hypothesis that the stratum-adjusted difference is zero. Difference, standard error of the difference, and the CI are stratum adjusted based on baseline ALT category (≤ 2 x ULN or > 2 x ULN).
[5] Other relevant estimation information:
  No text entered.



3.  Secondary:   Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96   [ Time Frame: Week 96 ]

Measure Type Secondary
Measure Title Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96
Measure Description No text entered.
Time Frame Week 96  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with available data were analyzed. Data included for participants who had discontinued unless the reason for discontinuation was unrelated to protocol criteria.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 234   122 
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96 
[Units: Percentage of participants]
 90.6   89.3 


Statistical Analysis 1 for Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96
Groups [1] All groups
Statistical Test Type [2] Superiority or Other
Statistical Method [3] Z-test
P Value [4] 0.672
Difference in proportions [5] 1.4
95% Confidence Interval -5.2 to 8.0
Standard Error of the mean (3.4)
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Details of power calculation, definition of non-inferiority margin, and other key parameters:
  No text entered.
[3] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[4] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  P-value corresponds to a Z-test of the null hypothesis that the stratum-adjusted difference is zero. Two-sided 95% confidence intervals, stratified by baseline ALT (baseline ALT ≤ 2 x ULN, > 2 x ULN), were used to evaluate treatment arm differences.
[5] Other relevant estimation information:
  No text entered.



4.  Secondary:   Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384   [ Time Frame: Weeks 144, 192, 240, 288, 336, and 384 ]

Measure Type Secondary
Measure Title Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384
Measure Description No text entered.
Time Frame Weeks 144, 192, 240, 288, 336, and 384  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Randomized and Treated Analysis Set. Data included for participants who had discontinued unless the reason for discontinuation was unrelated to protocol criteria. Participants with missing values related to protocol criteria or who added FTC to their open-label TDF regimen were considered to have failed to reach the endpoint.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 241   121 
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384 
[Units: Percentage of participants]
   
Week 144     
Participants Analyzed 
[Units: Participants]
 241   121 
Week 144   86.7   88.4 
Week 192     
Participants Analyzed 
[Units: Participants]
 238   121 
Week 192   84.0   86.8 
Week 240     
Participants Analyzed 
[Units: Participants]
 232   118 
Week 240   82.8   83.9 
Week 288     
Participants Analyzed 
[Units: Participants]
 231   117 
Week 288   80.5   82.9 
Week 336     
Participants Analyzed 
[Units: Participants]
 230   118 
Week 336   77.0   78.0 
Week 384     
Participants Analyzed 
[Units: Participants]
 230   118 
Week 384   74.3   76.3 

No statistical analysis provided for Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384



5.  Secondary:   Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480   [ Time Frame: Weeks 432 and 480 ]

Measure Type Secondary
Measure Title Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480
Measure Description No text entered.
Time Frame Weeks 432 and 480  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with observed data were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis. Data for participants who added emtricitabine to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 82   44 
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480 
[Units: Percentage of participants]
   
Week 432     
Participants Analyzed 
[Units: Participants]
 82   44 
Week 432   97.6   97.7 
Week 480     
Participants Analyzed 
[Units: Participants]
 78   40 
Week 480   100.0   100.0 

No statistical analysis provided for Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480



6.  Secondary:   Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480   [ Time Frame: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480 ]

Measure Type Secondary
Measure Title Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Measure Description No text entered.
Time Frame Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with observed data were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis. Data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 241   117 
Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480 
[Units: Log10 copies/mL]
Mean (Standard Deviation)
   
Week 48     
Participants Analyzed 
[Units: Participants]
 241   117 
Week 48   -4.57  (1.347)   -4.07  (1.331) 
Week 96     
Participants Analyzed 
[Units: Participants]
 220   109 
Week 96   -4.54  (1.400)   -4.74  (1.260) 
Week 144     
Participants Analyzed 
[Units: Participants]
 215   107 
Week 144   -4.61  (1.285)   -4.77  (1.285) 
Week 192     
Participants Analyzed 
[Units: Participants]
 205   105 
Week 192   -4.56  (1.371)   -4.75  (1.271) 
Week 240     
Participants Analyzed 
[Units: Participants]
 195   100 
Week 240   -4.59  (1.288)   -4.77  (1.303) 
Week 288     
Participants Analyzed 
[Units: Participants]
 189   96 
Week 288   -4.61  (1.310)   -4.81  (1.310) 
Week 336     
Participants Analyzed 
[Units: Participants]
 180   92 
Week 336   -4.61  (1.329)   -4.81  (1.307) 
Week 384     
Participants Analyzed 
[Units: Participants]
 174   89 
Week 384   -4.56  (1.333)   -4.79  (1.314) 
Week 432     
Participants Analyzed 
[Units: Participants]
 82   44 
Week 432   -4.60  (1.376)   -4.69  (1.370) 
Week 480     
Participants Analyzed 
[Units: Participants]
 78   40 
Week 480   -4.57  (1.329)   -4.75  (1.349) 

No statistical analysis provided for Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480



7.  Secondary:   Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480   [ Time Frame: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480 ]

Measure Type Secondary
Measure Title Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Measure Description No text entered.
Time Frame Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with observed data were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis. Data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 220   109 
Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480 
[Units: Log10 copies/mL]
Mean (Standard Deviation)
   
Week 96     
Participants Analyzed 
[Units: Participants]
 220   109 
Week 96   0.02  (0.424)   -0.60  (1.138) 
Week 144     
Participants Analyzed 
[Units: Participants]
 215   107 
Week 144   -0.03  (0.378)   -0.63  (1.169) 
Week 192     
Participants Analyzed 
[Units: Participants]
 205   105 
Week 192   0.01  (0.610)   -0.61  (1.161) 
Week 240     
Participants Analyzed 
[Units: Participants]
 195   100 
Week 240   -0.04  (0.299)   -0.61  (1.195) 
Week 288     
Participants Analyzed 
[Units: Participants]
 189   96 
Week 288   -0.04  (0.353)   -0.64  (1.203) 
Week 336     
Participants Analyzed 
[Units: Participants]
 180   92 
Week 336   -0.05  (0.380)   -0.65  (1.230) 
Week 384     
Participants Analyzed 
[Units: Participants]
 174   89 
Week 384   -0.02  (0.241)   -0.66  (1.237) 
Week 432     
Participants Analyzed 
[Units: Participants]
 82   44 
Week 432   -0.04  (0.393)   -0.67  (1.378) 
Week 480     
Participants Analyzed 
[Units: Participants]
 78   40 
Week 480   -0.05  (0.366)   -0.72  (1.283) 

No statistical analysis provided for Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480



8.  Secondary:   Percentage of Participants With Histological Response at Week 48   [ Time Frame: Baseline; Week 48 ]

Measure Type Secondary
Measure Title Percentage of Participants With Histological Response at Week 48
Measure Description Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.
Time Frame Baseline; Week 48  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Randomized and Treated Analysis Set; the missing-equals-failure approach was used where participants with missing data were considered to have failed to reach the endpoint.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 250   125 
Percentage of Participants With Histological Response at Week 48 
[Units: Percentage of participants]
   
Yes   72.4   68.8 
No   27.6   31.2 


Statistical Analysis 1 for Percentage of Participants With Histological Response at Week 48
Groups [1] All groups
Statistical Test Type [2] Superiority or Other
Statistical Method [3] Z-test
P Value [4] 0.293
Difference in proportions [5] 5.2
95% Confidence Interval -4.5 to 14.9
Standard Error of the mean (5.0)
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Details of power calculation, definition of non-inferiority margin, and other key parameters:
  No text entered.
[3] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[4] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  P-value corresponds to a Z-test of the null hypothesis that the stratum-adjusted difference is zero. Confidence interval stratum adjusted based on baseline ALT (≤ 2 x ULN, > 2 x ULN).
[5] Other relevant estimation information:
  No text entered.



9.  Secondary:   Percentage of Participants With Histological Response at Week 240   [ Time Frame: Baseline; Week 240 ]

Measure Type Secondary
Measure Title Percentage of Participants With Histological Response at Week 240
Measure Description Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.
Time Frame Baseline; Week 240  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with observed data were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis. Data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 150   74 
Percentage of Participants With Histological Response at Week 240 
[Units: Percentage of participants]
   
Yes   87.3   85.1 
No   12.7   14.9 

No statistical analysis provided for Percentage of Participants With Histological Response at Week 240



10.  Secondary:   Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48   [ Time Frame: Baseline; Week 48 ]

Measure Type Secondary
Measure Title Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48
Measure Description The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst).
Time Frame Baseline; Week 48  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with measurements at Baseline and Week 48 were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 234   113 
Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48 
[Units: Units on a scale]
Mean (Standard Deviation)
   
Knodell Necroinflammatory Score   -3.5  (2.50)   -3.4  (2.36) 
Ishak Necroinflammatory Score   -2.6  (1.93)   -2.6  (1.90) 

No statistical analysis provided for Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48



11.  Secondary:   Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240   [ Time Frame: Baseline; Week 240 ]

Measure Type Secondary
Measure Title Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240
Measure Description The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst).
Time Frame Baseline; Week 240  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with observed data were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis. Data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 150   74 
Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240 
[Units: Units on a scale]
Mean (Standard Deviation)
   
Knodell Score   -4.6  (2.50)   -4.9  (2.53) 
Ishak Score   -4.0  (2.16)   -4.2  (2.38) 

No statistical analysis provided for Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240



12.  Secondary:   Ranked Assessment of Necroinflammation and Fibrosis at Week 48   [ Time Frame: Baseline; Week 48 ]

Measure Type Secondary
Measure Title Ranked Assessment of Necroinflammation and Fibrosis at Week 48
Measure Description Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening.
Time Frame Baseline; Week 48  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Randomized and Treated Analysis Set; the missing-equals-failure approach was used where participants with missing data were considered to have failed to reach the endpoint.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 250   125 
Ranked Assessment of Necroinflammation and Fibrosis at Week 48 
[Units: Percentage of participants]
   
Improvement - Necroinflammation   82.0   81.6 
No Change - Necroinflammation   6.8   8.0 
Worsening - Necroinflammation   4.8   0.8 
Missing Data - Necroinflammation   6.4   9.6 
Improvement - Fibrosis   22.0   25.6 
No Change - Fibrosis   63.2   54.4 
Worsening - Fibrosis   8.4   10.4 
Missing Data - Fibrosis   6.4   9.6 

No statistical analysis provided for Ranked Assessment of Necroinflammation and Fibrosis at Week 48



13.  Secondary:   Ranked Assessment of Necroinflammation and Fibrosis at Week 240   [ Time Frame: Baseline; Week 240 ]

Measure Type Secondary
Measure Title Ranked Assessment of Necroinflammation and Fibrosis at Week 240
Measure Description Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening.
Time Frame Baseline; Week 240  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with observed data were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis. Data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 150   74 
Ranked Assessment of Necroinflammation and Fibrosis at Week 240 
[Units: Percentage of participants]
   
Improvement - Necroinflammation   96.7   94.6 
No Change - Necroinflammation   2.7   1.4 
Worsening - Necroinflammation   0.7   4.1 
Improvement - Fibrosis   62.0   59.5 
No Change - Fibrosis   34.0   33.8 
Worsening - Fibrosis   4.0   6.8 

No statistical analysis provided for Ranked Assessment of Necroinflammation and Fibrosis at Week 240



14.  Secondary:   Percentage of Participants With ALT Normalization at Week 48   [ Time Frame: Baseline; Week 48 ]

Measure Type Secondary
Measure Title Percentage of Participants With ALT Normalization at Week 48
Measure Description ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.
Time Frame Baseline; Week 48  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with ALT > ULN at baseline were analyzed; the missing-equals-failure approach was used where participants with missing data were considered to have failed to reach the endpoint.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 236   118 
Percentage of Participants With ALT Normalization at Week 48 
[Units: Percentage of participants]
 76.3   77.1 


Statistical Analysis 1 for Percentage of Participants With ALT Normalization at Week 48
Groups [1] All groups
Statistical Test Type [2] Superiority or Other
Statistical Method [3] Z-test
P Value [4] 0.859
Difference in proportions [5] -0.8
95% Confidence Interval -10.2 to 8.5
Standard Error of the mean (4.8)
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Details of power calculation, definition of non-inferiority margin, and other key parameters:
  No text entered.
[3] Other relevant method information, such as adjustments or degrees of freedom:
  P-value corresponds to a Z-test of the null hypothesis that the ALT stratum-adjusted difference is zero.
[4] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  Statistical tests were not adjusted for baseline ALT stratum. Analysis set included only randomized and treated participants with baseline ALT > ULN (biochemically evaluable analysis set).
[5] Other relevant estimation information:
  No text entered.



15.  Secondary:   Percentage of Participants With ALT Normalization at Weeks 96   [ Time Frame: Baseline; Week 96 ]

Measure Type Secondary
Measure Title Percentage of Participants With ALT Normalization at Weeks 96
Measure Description ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.
Time Frame Baseline; Week 96  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with ALT > ULN at baseline. Data included for participants who had discontinued unless the reason for discontinuation was unrelated to protocol criteria; data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 221   111 
Percentage of Participants With ALT Normalization at Weeks 96 
[Units: Percentage of participants]
 72.4   68.5 


Statistical Analysis 1 for Percentage of Participants With ALT Normalization at Weeks 96
Groups [1] All groups
Statistical Test Type [2] Superiority or Other
Statistical Method [3] Z-test
P Value [4] 0.359
Difference in proportions [5] 4.9
95% Confidence Interval -5.5 to 15.3
Standard Error of the mean (5.3)
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  No text entered.
[2] Details of power calculation, definition of non-inferiority margin, and other key parameters:
  No text entered.
[3] Other relevant method information, such as adjustments or degrees of freedom:
  Difference, standard error of the difference, and confidence interval are stratum adjusted (baseline ALT ≤ 2 x ULN or > 2 x ULN).
[4] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  P-value corresponds to a Z-test of the null hypothesis that the ALT stratum-adjusted difference is zero.
[5] Other relevant estimation information:
  No text entered.



16.  Secondary:   Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384   [ Time Frame: Baseline; Weeks 144, 192, 240, 288, 336, and 384 ]

Measure Type Secondary
Measure Title Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384
Measure Description ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.
Time Frame Baseline; Weeks 144, 192, 240, 288, 336, and 384  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with ALT > ULN at baseline and available data were analyzed. Data included for participants who had discontinued unless the reason for discontinuation was unrelated to protocol criteria; data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 226   110 
Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384 
[Units: Percentage of participants]
   
Week 144     
Participants Analyzed 
[Units: Participants]
 226   110 
Week 144   74.3   70.0 
Week 192     
Participants Analyzed 
[Units: Participants]
 223   110 
Week 192   68.2   76.4 
Week 240     
Participants Analyzed 
[Units: Participants]
 219   107 
Week 240   70.3   75.7 
Week 288     
Participants Analyzed 
[Units: Participants]
 216   107 
Week 288   69.9   72.9 
Week 336     
Participants Analyzed 
[Units: Participants]
 217   107 
Week 336   65.9   65.4 
Week 384     
Participants Analyzed 
[Units: Participants]
 216   107 
Week 384   65.3   69.2 

No statistical analysis provided for Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384



17.  Secondary:   Percentage of Participants With ALT Normalization at Weeks 432 and 480   [ Time Frame: Baseline; Weeks 432 and 480 ]

Measure Type Secondary
Measure Title Percentage of Participants With ALT Normalization at Weeks 432 and 480
Measure Description ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged ≥ 69.
Time Frame Baseline; Weeks 432 and 480  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with ALT > ULN at baseline and with observed data were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis. Data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 74   39 
Percentage of Participants With ALT Normalization at Weeks 432 and 480 
[Units: Percentage of participants]
   
Week 432     
Participants Analyzed 
[Units: Participants]
 74   39 
Week 432   86.5   87.2 
Week 480     
Participants Analyzed 
[Units: Participants]
 70   36 
Week 480   80.0   88.9 

No statistical analysis provided for Percentage of Participants With ALT Normalization at Weeks 432 and 480



18.  Secondary:   Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480   [ Time Frame: Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480 ]

Measure Type Secondary
Measure Title Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Measure Description No text entered.
Time Frame Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with observed data were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis. Data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 240   117 
Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480 
[Units: Units per liter]
Mean (Standard Deviation)
   
Week 48     
Participants Analyzed 
[Units: Participants]
 240   117 
Week 48   -95.0  (102.31)   -124.4  (137.23) 
Week 96     
Participants Analyzed 
[Units: Participants]
 219   108 
Week 96   -93.7  (106.66)   -138.5  (155.75) 
Week 144     
Participants Analyzed 
[Units: Participants]
 214   106 
Week 144   -99.1  (105.67)   -140.0  (155.43) 
Week 192     
Participants Analyzed 
[Units: Participants]
 204   104 
Week 192   -99.6  (109.46)   -140.3  (153.89) 
Week 240     
Participants Analyzed 
[Units: Participants]
 196   100 
Week 240   -97.7  (104.32)   -139.5  (156.90) 
Week 288     
Participants Analyzed 
[Units: Participants]
 187   97 
Week 288   -98.9  (104.66)   -134.7  (152.90) 
Week 336     
Participants Analyzed 
[Units: Participants]
 180   92 
Week 336   -98.9  (106.50)   -143.1  (160.15) 
Week 384     
Participants Analyzed 
[Units: Participants]
 172   89 
Week 384   -96.1  (105.43)   -132.6  (142.09) 
Week 432     
Participants Analyzed 
[Units: Participants]
 82   43 
Week 432   -97.0  (115.09)   -131.9  (136.65) 
Week 480     
Participants Analyzed 
[Units: Participants]
 78   40 
Week 480   -94.9  (117.60)   -129.2  (139.24) 

No statistical analysis provided for Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480



19.  Secondary:   Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480   [ Time Frame: Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480 ]

Measure Type Secondary
Measure Title Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Measure Description No text entered.
Time Frame Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set with observed data were analyzed; the missing-equals-excluded approach was used where participants with missing data were excluded from the analysis. Data for participants who added FTC to their open-label TDF regimen were included in the analysis.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 219   108 
Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480 
[Units: Units per liter]
Mean (Standard Deviation)
   
Week 96     
Participants Analyzed 
[Units: Participants]
 219   108 
Week 96   2.4  (22.01)   -0.6  (19.87) 
Week 144     
Participants Analyzed 
[Units: Participants]
 214   106 
Week 144   -0.6  (12.91)   -0.3  (22.48) 
Week 192     
Participants Analyzed 
[Units: Participants]
 204   104 
Week 192   0.7  (23.07)   -3.6  (22.77) 
Week 240     
Participants Analyzed 
[Units: Participants]
 196   100 
Week 240   -2.5  (14.64)   -3.9  (20.00) 
Week 288     
Participants Analyzed 
[Units: Participants]
 187   97 
Week 288   -3.9  (13.35)   -4.1  (22.30) 
Week 336     
Participants Analyzed 
[Units: Participants]
 180   92 
Week 336   -2.6  (15.69)   -2.0  (20.61) 
Week 384     
Participants Analyzed 
[Units: Participants]
 172   89 
Week 384   -2.9  (14.13)   -3.9  (21.00) 
Week 432     
Participants Analyzed 
[Units: Participants]
 82   43 
Week 432   -4.6  (15.65)   -8.9  (29.12) 
Week 480     
Participants Analyzed 
[Units: Participants]
 78   40 
Week 480   -2.8  (15.92)   -5.9  (24.12) 

No statistical analysis provided for Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480



20.  Secondary:   Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48   [ Time Frame: Baseline; Week 48 ]

Measure Type Secondary
Measure Title Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48
Measure Description HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48.
Time Frame Baseline; Week 48  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set were analyzed. The missing = failure approach was used.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 250   125 
Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48 
[Units: Percentage of participants]
   
HBsAg Loss   0   0 
Seroconversion to anti-HBs   0   0 

No statistical analysis provided for Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48



21.  Secondary:   Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96   [ Time Frame: Baseline; Week 96 ]

Measure Type Secondary
Measure Title Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96
Measure Description HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 96. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 96.
Time Frame Baseline; Week 96  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Randomized and Treated Analysis Set. Data is included for participants who had discontinued unless the reason for discontinuation was unrelated to protocol criteria.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 242   121 
Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96 
[Units: Percentage of participants]
   
HBsAg Loss   0   0 
Anti-HBs Seroconversion   0   0 

No statistical analysis provided for Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96



22.  Secondary:   Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480   [ Time Frame: Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480 ]

Measure Type Secondary
Measure Title Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480
Measure Description HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point.
Time Frame Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Randomized and Treated Analysis Set. Data is included for participants who had discontinued unless the reason for discontinuation was unrelated to protocol criteria. Participants with missing values related to protocol criteria or who added FTC to their open-label TDF regimen were considered to have failed to reach the endpoint.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 250   123 
Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480 
[Units: Percentage of participants]
   
HBsAg Loss - Week 144     
Participants Analyzed 
[Units: Participants]
 246   120 
HBsAg Loss - Week 144   0   0 
Anti-HBs Seroconversion - Week 144     
Participants Analyzed 
[Units: Participants]
 246   120 
Anti-HBs Seroconversion - Week 144   0   0 
HBsAg Loss - Week 192     
Participants Analyzed 
[Units: Participants]
 247   122 
HBsAg Loss - Week 192   0   0 
Anti-HBs Seroconversion - Week 192     
Participants Analyzed 
[Units: Participants]
 247   122 
Anti-HBs Seroconversion - Week 192   0   0 
HBsAg Loss - Week 240     
Participants Analyzed 
[Units: Participants]
 246   121 
HBsAg Loss - Week 240   0   0.8 
Anti-HBs Seroconversion - Week 240     
Participants Analyzed 
[Units: Participants]
 246   121 
Anti-HBs Seroconversion - Week 240   0   0 
HBsAg Loss - Week 288     
Participants Analyzed 
[Units: Participants]
 246   120 
HBsAg Loss - Week 288   0   0.8 
Anti-HBs Seroconversion - Week 288     
Participants Analyzed 
[Units: Participants]
 246   120 
Anti-HBs Seroconversion - Week 288   0   0.8 
HBsAg Loss - Week 336     
Participants Analyzed 
[Units: Participants]
 248   123 
HBsAg Loss - Week 336   0   0.8 
Anti-HBs Seroconversion - Week 336     
Participants Analyzed 
[Units: Participants]
 248   123 
Anti-HBs Seroconversion - Week 336   0   0.8 
HBsAg Loss - Week 384     
Participants Analyzed 
[Units: Participants]
 248   122 
HBsAg Loss - Week 384   0.8   0.8 
Anti-HBs Seroconversion - Week 384     
Participants Analyzed 
[Units: Participants]
 248   122 
Anti-HBs Seroconversion - Week 384   0.4   0.8 
HBsAg Loss - Week 432     
Participants Analyzed 
[Units: Participants]
 250   122 
HBsAg Loss - Week 432   1.2   1.6 
Anti-HBs Seroconversion - Week 432     
Participants Analyzed 
[Units: Participants]
 248   122 
Anti-HBs Seroconversion - Week 432   0.4   0.8 
HBsAg Loss - Week 480     
Participants Analyzed 
[Units: Participants]
 250   123 
HBsAg Loss - Week 480   1.2   2.4 
Anti-HBs Seroconversion - Week 480     
Participants Analyzed 
[Units: Participants]
 250   123 
Anti-HBs Seroconversion - Week 480   0.8   0.8 

No statistical analysis provided for Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480



23.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)   [ Time Frame: Baseline; Week 48 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 48, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA ≥ 400 copies/mL.
Time Frame Baseline; Week 48  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC to their treatment regimen (as part of FTC 200 mg/TDF 300 mg FDC tablet) in the open-label period.

Measured Values
   TDF-TDF   ADV-TDF 
Participants Analyzed 
[Units: Participants]
 250   125 
Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance) 
[Units: Participants]
   
Participants evaluated   8   42 
Changes at conserved sites in HBV polymerase   0   7 
Changes at polymorphic sites in HBV polymerase   3   14 
No genotypic changes (wild-type virus)   4   20 
Unable to be genotyped   1   1 

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)



24.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)   [ Time Frame: Baseline; Weeks 49 to 96 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA ≥ 400 copies/mL at the time of the addition.
Time Frame Baseline; Weeks 49 to 96  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set who continued on the study after Week 48 (ie, entered the open-label phase) were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
TDF-TDF With Addition of FTC TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
ADV-TDF With Addition of FTC ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.

Measured Values
   TDF-TDF   TDF-TDF With Addition of FTC   ADV-TDF   ADV-TDF With Addition of FTC 
Participants Analyzed 
[Units: Participants]
 235   2   112   0 
Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance) 
[Units: Participants]
       
Participants evaluated   6   1   0    
Changes at conserved sites within HBV polymerase   0   0   0    
Changes at polymorphic sites in HBV polymerase   2   1   0    
No genotypic changes (wild-type virus)   4   0   0    
Unable to be genotyped   0   0   0    

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)



25.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)   [ Time Frame: Baseline; Weeks 97 to 144 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA ≥ 400 copies/mL at the time of the addition.
Time Frame Baseline; Weeks 97 to 144  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set who continued on the study after Week 96 with available data were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
TDF-TDF With Addition of FTC TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
ADV-TDF With Addition of FTC ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.

Measured Values
   TDF-TDF   TDF-TDF With Addition of FTC   ADV-TDF   ADV-TDF With Addition of FTC 
Participants Analyzed 
[Units: Participants]
 220   3   110   0 
Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance) 
[Units: Participants]
       
Participants evaluated   4   0   0    
Changes at conserved sites within HBV polymerase   0   0   0    
Changes at polymorphic sites in HBV polymerase   1   0   0    
No genotypic changes (wild-type virus)   2   0   0    
Unable to genotype   1   0   0    

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)



26.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)   [ Time Frame: Baseline; Weeks 145 to 192 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA ≥ 400 copies/mL at the time of the addition.
Time Frame Baseline; Weeks 145 to 192  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set who continued on the study after Week 144 with available data were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
TDF-TDF With Addition of FTC TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
ADV-TDF With Addition of FTC ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.

Measured Values
   TDF-TDF   TDF-TDF With Addition of FTC   ADV-TDF   ADV-TDF With Addition of FTC 
Participants Analyzed 
[Units: Participants]
 215   3   109   0 
Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance) 
[Units: Participants]
       
Participants evaluated   3   1   0    
Changes at conserved sites within HBV polymerase   0   0   0    
Changes at polymorphic sites in HBV polymerase   1   0   0    
No genotypic changes (wild-type virus)   1   1   0    
Unable to genotype   1   0   0    

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)



27.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)   [ Time Frame: Baseline; Weeks 193 to 240 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA ≥ 400 copies/mL at the time of the addition.
Time Frame Baseline; Weeks 193 to 240  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set who continued on the study after Week 192 with available data were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
TDF-TDF With Addition of FTC TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
ADV-TDF With Addition of FTC ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.

Measured Values
   TDF-TDF   TDF-TDF With Addition of FTC   ADV-TDF   ADV-TDF With Addition of FTC 
Participants Analyzed 
[Units: Participants]
 204   3   105   0 
Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance) 
[Units: Participants]
       
Participants evaluated   1   2   2    
Changes at conserved sites within HBV polymerase   1   0   0    
Changes at polymorphic sites in HBV polymerase   0   2   0    
No genotypic changes (wild-type virus)   0   0   0    
Unable to genotype   0   0   2    

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)



28.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)   [ Time Frame: Baseline; Weeks 241 to 288 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA ≥ 400 copies/mL at the time of the addition.
Time Frame Baseline; Weeks 241 to 288  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set who continued on the study after Week 240 with available data were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
TDF-TDF With Addition of FTC TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
ADV-TDF With Addition of FTC ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.

Measured Values
   TDF-TDF   TDF-TDF With Addition of FTC   ADV-TDF   ADV-TDF With Addition of FTC 
Participants Analyzed 
[Units: Participants]
 195   3   102   0 
Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance) 
[Units: Participants]
       
Participants evaluated   3   1   1    
Changes at conserved sites within HBV polymerase   0   0   0    
Changes at polymorphic sites in HBV polymerase   2   1   1    
No genotypic changes (wild-type virus)   1   0   0    
Unable to genotype   0   0   0    

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)



29.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)   [ Time Frame: Baseline; Weeks 289 to 336 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA ≥ 400 copies/mL at the time of the addition.
Time Frame Baseline; Weeks 289 to 336  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set who continued on the study after Week 288 with available data were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
TDF-TDF With Addition of FTC TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
ADV-TDF With Addition of FTC ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.

Measured Values
   TDF-TDF   TDF-TDF With Addition of FTC   ADV-TDF   ADV-TDF With Addition of FTC 
Participants Analyzed 
[Units: Participants]
 189   3   97   0 
Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance) 
[Units: Participants]
       
Participants evaluated   0   1   1    
Changes at conserved sites within HBV polymerase   0   0   0    
Changes at polymorphic sites in HBV polymerase   0   0   0    
No genotypic changes (wild-type virus)   0   1   0    
Unable to genotype   0   0   1    

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)



30.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)   [ Time Frame: Baseline; Weeks 337 to 384 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA ≥ 400 copies/mL at the time of the addition.
Time Frame Baseline; Weeks 337 to 384  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set who continued on the study after Week 336 with available data were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
TDF-TDF With Addition of FTC TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
ADV-TDF With Addition of FTC ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.

Measured Values
   TDF-TDF   TDF-TDF With Addition of FTC   ADV-TDF   ADV-TDF With Addition of FTC 
Participants Analyzed 
[Units: Participants]
 177   3   92   0 
Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance) 
[Units: Participants]
       
Participants evaluated   1   0   0    
Changes at conserved sites within HBV polymerase   0   0   0    
Changes at polymorphic sites in HBV polymerase   0   0   0    
No genotypic changes (wild-type virus)   0   0   0    
Unable to genotype   1   0   0    

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)



31.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)   [ Time Frame: Baseline; Weeks 385 to 432 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 432 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 384 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 384 and had HBV DNA ≥ 400 copies/mL at the time of the addition.
Time Frame Baseline; Weeks 385 to 432  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set who continued on the study after Week 384 with available data were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
TDF-TDF With Addition of FTC TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
ADV-TDF With Addition of FTC ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.

Measured Values
   TDF-TDF   TDF-TDF With Addition of FTC   ADV-TDF   ADV-TDF With Addition of FTC 
Participants Analyzed 
[Units: Participants]
 81   1   46   0 
Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance) 
[Units: Participants]
       
Participants evaluated   2   0   1    
Changes at conserved sites within HBV polymerase   0   0   0    
Changes at polymorphic sites in HBV polymerase   0   0   1    
No genotypic changes (wild-type virus)   2   0   0    
Unable to genotype   0   0   0    

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)



32.  Secondary:   Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)   [ Time Frame: Baseline; Weeks 433 to 480 ]

Measure Type Secondary
Measure Title Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)
Measure Description Of the total number analyzed, participants evaluated for resistance included those with HBV DNA ≥ 400 copies/mL at Week 480 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 432 with HBV DNA ≥ 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 432 and had HBV DNA ≥ 400 copies/mL at the time of the addition.
Time Frame Baseline; Weeks 433 to 480  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants in the Randomized and Treated Analysis Set who continued on the study after Week 432 with available data were analyzed to determine if they qualified for protocol criteria for resistance surveillance, and those meeting the criteria were evaluated.

Reporting Groups
  Description
TDF-TDF TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
TDF-TDF With Addition of FTC TDF 300 mg plus placebo to match ADV (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.
ADV-TDF ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group did not add FTC to their study regimen in the open-label period.
ADV-TDF With Addition of FTC ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants in this reporting group added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their study regimen in the open-label period.

Measured Values
   TDF-TDF   TDF-TDF With Addition of FTC   ADV-TDF   ADV-TDF With Addition of FTC 
Participants Analyzed 
[Units: Participants]
 81   1   43   0 
Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance) 
[Units: Participants]
       
Participants evaluated   0   0   0    
Changes at conserved sites within HBV polymerase   0   0   0    
Changes at polymorphic sites in HBV polymerase   0   0   0    
No genotypic changes (wild-type virus)   0   0   0    
Unable to genotype   0   0   0    

No statistical analysis provided for Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)




  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information